Denali Therapeutics (NASDAQ: DNLI)
Denali Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Denali Therapeutics Company Info
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
News & Analysis
Why Shares of Denali Therapeutics Are Up Monday
Analysts maintained their buy ratings on the clinical-stage biotech company.
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Why Denali Therapeutics Stock Is Sinking This Week
The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
Why Denali Therapeutics Stock Is Sinking Today
The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.
Why Denali Therapeutics Stock Popped Today
The biotech received good news from the FDA concerning one of its pipeline candidates.
3 Best Biotech Stocks to Buy in November
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
Sanofi and Denali Halt Clinical Trials of Alzheimer Drug
The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.
Why Denali Therapeutics Stock Is Soaring Today
Shares jump after the company releases upbeat clinical news.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.